Leslie J. Browne

Who is Leslie J. Browne?

Dr. Browne has over twenty years of experience in the pharmaceutical

industry across multiple disciplines including Research

Development, Operations, and Business Development. Prior to joining

Pharmacopeia, Dr. Browne was the Chief Operating Officer at Iconix

Pharmaceuticals, Inc., a leading chemogenomics company, where he led

the research, development and informatics operations and launched

Iconix's first product, DrugMatrix®. Before joining Iconix Dr. Browne

held several positions at Berlex/Schering AG, including Corporate Vice

President, Berlex Laboratories, Inc. and President of Schering Berlin

Venture Corporation. At Berlex Biosciences he rebuilt the drug

discovery operation and championed a number of important pharma-biotech

deals for Berlex, including a combinatorial chemistry collaboration

with Pharmacopeia. Before Berlex, he was with Ciba-Geigy, where he

discovered Fadrozole, the first marketed non-steroidal aromatase

inhibitor for the treatment of estrogen-dependent breast cancer. He

also managed cardiovascular research at Ciba-Geigy Ltd., in Basle,

where one of the group's achievements was the discovery of Diovan®, the

second angiotensin II antagonist ever to be marketed. Over his career,

Dr. Browne has authored numerous publications and patents covering a

broad range of therapeutic areas including CNS, cardiovascular disease,

inflammation and cancer. Dr. Browne received his B.Sc. at Strathclyde

University, in Glasgow, Scotland. After receiving his Ph.D. from the

University of Michigan, he was a National Institutes of Health

postdoctoral fellow at Harvard with the Nobel laureate Professor R. B.

Woodward.